Clinical trials

These clinical trials are currently open for recruitment.

Phase I open label clinical trial of autologous T cell therapy for the treatment of cytomegalovirus (CMV) reactivation and disease after transplantation

Summary: This study looks at the feasibility of growing CMV-specific killer T cells from the blood of solid organ transplant recipients with active CMV infection, and the safety of infusing these cells into patients. Blood will be collected from patients and the CMV-specific killer T cells grown in the laboratory. The cells will be infused into patients at 2-weekly intervals (four doses) and then at 4-weekly intervals (2 doses). Patients will receive a minimum of two doses and a maximum of six doses of T cells, depending on the number of cells grown.

More information: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364871

Phase I/II trial to assess safety and tolerability of autologous HCMV-specific T cell therapy as adjuvant treatment for glioblastoma multiforme

Recent studies suggest that most gliomas (a type of brain tumour) carry a common virus, called human cytomegalovirus (HCMV), which is normally controlled by killer T cells. The study aims to see if killer T cells grown in the laboratory and trained to recognise and kill the virus can also kill HCMV-infected glioblastoma multiforme (GBM). This study looks at the safety and effectiveness of using T cell therapy targeting HCMV in treating GBM. Participants will receive treatment with killer T cells (a type of white blood cell) which have been grown in the laboratory from the patient’s own cells. Patients will be eligible the trial if they have recently been diagnosed with GBM and are about to begin standard radiotherapy and chemotherapy regimens. A blood sample will be taken from patients prior to beginning standard radiotherapy and chemotherapy, in order to grow the cells for the experimental therapy. Patients will receive a minimum of two doses and a maximum of six doses of T cells, depending on the number of cells grown.

More information: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364642


Phase I/II open-label clinical trial of autologous Epstein-Barr virus-specific T cell therapy as consolidative treatment following chemotherapy for metastatic EBV-associated nasopharyngeal carcinoma

Summary: Epstein-Barr virus (EBV) is associated with a number of human malignancies including nasopharyngeal carcinoma (NPC). We are attempting to develop immunotherapy as an alternate treatment for NPC in addition to radiotherapy, chemotherapy and surgery. This immunotherapy requires that a white blood cells known as killer T cells be isolated from the NPC patient’s blood. These T cells are trained in the laboratory to become more efficient at recognising and destroying EBV-infected tumour cells. Patients will be enrolled following initial diagnosis, and blood sample will be taken prior to beginning standard chemotherapy, in order to grow the cells for the experimental therapy. The EBV-specific T cells will then be infused into patients following chemotherapy. Patients will receive a minimum of two doses and a maximum of six doses of T cells, depending on the number of cells grown.

More information: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364641

Bookmark and Share